羟氯喹：一种伪装成糖尿病药物的药物？
Hydroxychloroquine: a diabetic drug in disguise?
作者信息
Kang Lydia, Mikuls Ted R, O'Dell James R
机构信息
University of Nebraska Medical Center, General Internal Medicine, MSB 5544, 983331, Omaha, Nebraska, 68198-3331, USA.
出版信息
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.08.2008.0654. Epub 2009 Mar 2.
Abstract
Hydroxychloroquine (HCQ) is an antimalarial agent that is commonly used to treat rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The present report documents a case of hypoglycaemia due to HCQ in a patient with SLE and diabetes mellitus type 2, in which the HCQ completely replaced the need for daily subcutaneous insulin.
摘要
羟氯喹（HCQ）是一种抗疟药，常用于治疗类风湿关节炎（RA）和系统性红斑狼疮（SLE）。本报告记录了1例2型糖尿病合并SLE患者因服用HCQ导致低血糖的病例，在此病例中HCQ完全取代了每日皮下注射胰岛素的需求。
相似文献
1
Hydroxychloroquine: a diabetic drug in disguise?羟氯喹：一种伪装成糖尿病药物的药物？
BMJ Case Rep. 2009;2009. doi: 10.1136/bcr.08.2008.0654. Epub 2009 Mar 2.
2
Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.羟氯喹与类风湿关节炎和系统性红斑狼疮女性患者的血糖。
J Rheumatol. 2010 Jun;37(6):1136-42. doi: 10.3899/jrheum.090994. Epub 2010 May 1.
3
Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.羟氯喹在皮肤红斑狼疮患者中的稳态药代动力学。
Lupus. 2018 Apr;27(5):847-852. doi: 10.1177/0961203317727601. Epub 2017 Sep 1.
4
Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study.羟氯喹以剂量依赖方式降低狼疮患者新发糖尿病的风险：一项基于人群的队列研究。
Rheumatology (Oxford). 2015 Jul;54(7):1244-9. doi: 10.1093/rheumatology/keu451. Epub 2015 Jan 12.
5
Hydroxychloroquine in systemic lupus erythematosus (SLE).羟氯喹在系统性红斑狼疮（SLE）中的应用。
Expert Opin Drug Saf. 2017 Mar;16(3):411-419. doi: 10.1080/14740338.2017.1269168. Epub 2016 Dec 14.
6
Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study.羟氯喹不会增加常见风湿性疾病中心律失常的风险：一项全国范围内基于人群的队列研究。
Front Immunol. 2021 Apr 2;12:631869. doi: 10.3389/fimmu.2021.631869. eCollection 2021.
7
Retinal toxicity related to hydroxychloroquine in patients with systemic lupus erythematosus and rheumatoid arthritis.系统性红斑狼疮和类风湿关节炎患者中与羟氯喹相关的视网膜毒性
Doc Ophthalmol. 2017 Dec;135(3):187-194. doi: 10.1007/s10633-017-9607-9. Epub 2017 Aug 29.
8
Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).专家小组共识意见：抗炎药物在2型糖尿病（T2D）管理中的作用
J Assoc Physicians India. 2019 Dec;67(12):65-74.
9
Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus.羟氯喹抑制系统性红斑狼疮中 Th17 细胞的分化。
J Rheumatol. 2018 Jun;45(6):818-826. doi: 10.3899/jrheum.170737. Epub 2018 Mar 15.
10
Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.羟氯喹在系统性红斑狼疮和类风湿关节炎中的应用及其在妊娠期的安全性。
Expert Opin Drug Saf. 2011 Sep;10(5):705-14. doi: 10.1517/14740338.2011.566555. Epub 2011 Mar 22.
引用本文的文献
1
SGLT-2 inhibitors: new horizons for rheumatologists.SGLT-2 抑制剂：风湿病学家的新视野。
Curr Opin Rheumatol. 2024 Sep 1;36(5):351-359. doi: 10.1097/BOR.0000000000001030. Epub 2024 Jul 24.
2
Coronary artery disease (CAD) risk factor analysis in an age-stratified hospital population with systemic lupus erythematosus (SLE).对患有系统性红斑狼疮（SLE）的年龄分层医院人群进行冠状动脉疾病（CAD）风险因素分析。
Int J Cardiol Hypertens. 2020 Oct 14;7:100056. doi: 10.1016/j.ijchy.2020.100056. eCollection 2020 Dec.
3
Hydroxychloroquine-induced hypoglycaemia in non-diabetic renal patient on peritoneal dialysis.羟氯喹引起接受腹膜透析的非糖尿病肾病患者低血糖症。
BMJ Case Rep. 2018 Apr 18;2018:bcr-2017-223639. doi: 10.1136/bcr-2017-223639.
4
Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.风湿性疾病的免疫调节治疗：对糖尿病患者的影响
Curr Diab Rep. 2016 Oct;16(10):91. doi: 10.1007/s11892-016-0792-9.
5
A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role.羟氯喹除了具有抗炎作用外，对葡萄糖和脂质代谢也有有益影响。
Ther Adv Endocrinol Metab. 2014 Aug;5(4):77-85. doi: 10.1177/2042018814547204.
本文引用的文献
1
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis.羟氯喹与类风湿关节炎患者的糖尿病风险
JAMA. 2007 Jul 11;298(2):187-93. doi: 10.1001/jama.298.2.187.
2
Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older.美国国家健康和营养检查调查（NHANES）III中60岁及以上参与者的类风湿性关节炎和糖尿病患病率
J Rheumatol. 2007 Mar;34(3):469-73. Epub 2007 Dec 15.
3
The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial.羟氯喹对磺脲类药物治疗无效的2型糖尿病患者的疗效——一项随机试验。
Diabetes Res Clin Pract. 2002 Mar;55(3):209-19. doi: 10.1016/s0168-8227(01)00325-4.
4
The inhibition of gluconeogenesis by chloroquine contributes to its hypoglycaemic action.氯喹对糖异生的抑制作用有助于其降血糖作用。
Eur J Pharmacol. 2001 Oct 12;428(3):381-8. doi: 10.1016/s0014-2999(01)01221-3.
5
Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent.羟氯喹对糖尿病大鼠的胰岛素节省作用呈浓度依赖性。
Can J Physiol Pharmacol. 1999 Feb;77(2):118-23.
6
Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis.羟氯喹诱发的低血糖症发生在一名因多关节炎接受治疗的II型糖尿病患者身上。
J Rheumatol. 1999 Jan;26(1):195-6.
7
Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns.对抗疟药治疗患者的眼科监测：最佳实践模式
J Rheumatol. 1997 Jul;24(7):1390-2.
8
Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis.羟氯喹在巴尔的摩狼疮队列中的应用：对脂质、血糖和血栓形成的影响。
Lupus. 1996 Jun;5 Suppl 1:S16-22.
9
In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance.在一名患有严重胰岛素抵抗的糖尿病患者体内，氯喹诱导的胰岛素降解抑制作用。
Diabetes. 1984 Dec;33(12):1133-7. doi: 10.2337/diab.33.12.1133.
10
Effect of chloroquine on insulin and glucose homeostasis in normal subjects and patients with non-insulin dependent diabetes mellitus.氯喹对正常人和非胰岛素依赖型糖尿病患者胰岛素及葡萄糖稳态的影响。
Br Med J (Clin Res Ed). 1987 Apr 4;294(6576):900-1. doi: 10.1136/bmj.294.6576.900-c.
Zotero 插件